FDA clears Novartis’ new treatment for nAMD

Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more

© All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

JOIN OUR NEWSLETTER

JOIN OUR NEWSLETTER
Close